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Parasite–host cell interactionTo produce an infection Trypanosoma cruzi must evade lysis by the complement system. During
early stages of infection, the lectin pathway plays an important role in host defense and can be
activated by binding of mannan-binding lectin (MBL) to carbohydrates on the surface of pathogens.
We hypothesized that MBL has a dual role during parasite-host cell interaction as lectin complement
pathway activator and as binding molecule to invade the host cell. We used two polarized strains of
T. cruzi, R4 (susceptible) and 860 (resistant) strains, to investigate the role of MBL in complement-
mediated lysis. Interestingly R4, but not 860 metacyclic strain, markedly increases the invasion of
host cells, suggesting that MBL drives the invasion process while the parasite deactivates the Lectin
complement pathway.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Chagas’ disease (CD) affects several million people worldwide,
mostly in Latin America, being considered one of the most impor-
tant neglected tropical diseases and a global health problem [1].
This disease is caused by an obligate intracellular protozoan para-
site, Trypanosoma cruzi, transmitted mainly by triatomine bugs.
The parasite replicates inside host cells and evades immune system
recognition, causing a life-longing disease. Clinical manifestations
de CD include digestive, neurologic and especially cardiac symp-
toms, which may progress from arrhythmia to heart failure [2].
The complement system is one of the ﬁrst mechanisms of innate
immunity against pathogen infection, which culminates with the
formation of a membrane attack complex leading to pathogen lysis.
There are three pathways of complement activation: the classical,
the alternative and the lectin pathway. At early stages of infection,
the lectin pathway plays an important role in the host defense and
can be activated by the binding of mannan-binding lectin (MBL),L-Ficolin, H-Ficolin and M-Ficolin to carbohydrates on pathogens
surface [3,4]. In order to succeed the infection, T. cruzi needs to cir-
cumvent complement activation by producing a series of inhibitory
proteins such as Crit [5], CRP [6] and Calreticulin [7].
MBL is a recognition molecule of the collectin family that has a
central role in the activation of the lectin pathway. MBL forms
complexes with MBL-associated serine proteases (MASPs) and rec-
ognizes the terminal mannose or N-acetylglucosamine (GlcNAc)
residues on glycoproteins or carbohydrate polymers on pathogen
surface, in a Ca-dependent manner, resulting in pathogen opsoni-
zation and complement activation [8].
MBL deﬁciency is the most common form of congenital immune
deﬁciency, with a prevalence of approximately 10% in European
populations. Clinically signiﬁcant defects in MBL serum level were
associated with recurrent bacterial infection. Although MBL levels
may differ between individuals with the same MBL2 genotypes,
MBL levels are mostly genetically determined. Increased MBL lev-
els are associated with high secretor MBL genotypes, related to
MBL2 gene polymorphisms in both promoter and structural (exon
1) regions [9]. On the other hand, null and low producing MBL hap-
lotypes are to be found in 22% and 13% of the world’s population,
respectively [10].
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to T. cruzi infection, with higher parasite load, cardiomyopathy and
ﬁbrosis when compared to normal mice [11]. MBL deﬁciency was
also associated with infection by the enteric protozoa Cryptospori-
dium in children [12]. MBL levels were also correlated with clinical
outcome of CD patients, with acute symptoms related to increased
MBL levels in serum in comparison to asymptomatic and indeter-
minate forms [11]. In addition, high levels of MBL (>1000 ng/ml)
were associated with the severity of cardiomyopathy in CD, which
may be related to the pro-inﬂammatory role of MBL [13].
Other components of the lectin pathway were also shown to be
associated with susceptibility to CD and disease outcome. Lower L-
ﬁcolin levels, correlated to 258S variant, were associated with CD
susceptibility and severity of the disease [14]. Furthermore,
MASP2⁄CD genotypes resulting in low MASP-2 levels were related
to increased risk of chagasic cardiomyopathy. Low levels of MASP-
2 could result in inefﬁcient lectin pathway activation and therefore
favor parasite infection and disease progression [15]. T. cruzi acti-
vates the lectin pathway through the rapid binding of MBL, L-Fico-
lin and H-Ficolin to glycosylated molecules in the surface of
metacyclic trypomastigotes forms. Complement activation using
human serum depleted of MBL and ﬁcolins resulted in almost
70% decrease of C3b and C4b deposition on parasite surface and
complement-mediated lysis. The ability to resist complement sys-
tem killing and to invade the host cells to progress in infection is
known to differ among T. cruzi strains [16,17].
It has been reported that T. cruzi uses a complex repertoire of
molecules and mechanisms to invade host cells [18,19]. Here, we
hypothesize that some strains of T. cruzi use MBL to invade host
cells before complete activation of complement through the lectin
pathway; while other strains may activate mechanisms to inhibit
the efﬁcient MBL-dependent infection.
2. Methods
2.1. Parasites and cells
T. cruzi epimastigote forms from 860 and R4 strains were culti-
vated in liver infusion tryptose (LIT) medium supplemented with
10% fetal bovine serum at 27 C [20]. Metacyclic trypomastigotes
were obtained from grown epimastigote cultures cultivated in
GRACE medium (Sigma–Aldrich, USA) for 10–15 days and puriﬁed
using DEAE-cellulose columns in ice-cold PSG buffer (3.8 mM KH2-
PO4, 57.2 mM Na2HPO4, 44.5 mM NaCl, 55.5 mM C6H12O6, pH 8.0).
Vero cells were grown in RPMI 1640 (Sigma–Aldrich, USA) sup-
plemented with 10% fetal bovine serum (Gibco, USA), 2 mM L-glu-
tamine, 100 g/mL streptomycin and 100 U/mL penicilin in a
humidiﬁed incubator at 37 C and 5% CO2.
2.2. Human serum
Normal human serum (NHS; MBL > 1000 ng/mL) and MBL deﬁ-
cient human serum (DMBL > 100 ng/mL) were obtained from vol-
untary donors. MBL levels were previously determined using
ELISA kit (Antibodyshop, Denmark). Recombinat MBL (rMBL)
(R&D systems) was used in the complement-mediated lysis and
cell invasion essays.
2.3. Complement mediated-lysis assay
Complement assays were carried out as previously described
[5]. In brief, T. cruzi epimastigotes or metacyclic trypomastigotes
at 5.0  106 parasites/100 lL in serum-free RPMI, were incubated
with 100 lL of 25% or 50% NHS, DMBL or RPMI only (as negative
control) for 15 and 30 min at 37 C. Reactions were stopped upon
the addition of 800 lL ice-cold RPMI.In assays blocking classical and lectin pathways activation, epi-
mastigote forms (5.0  105 in 100 lL) resuspended in serum-free
RPMI were incubated with both 100 lL of 10% NHS or 10% DMBL
with 10 mM ethylene glycol tetraacetic acid (EGTA) for 15 or
30 min at 37 C. Reactions were stopped as described above.
Viable parasites were then counted in a Neubauer chamber un-
der light microscopy.
2.4. Western blotting
Parasites from both 860 and R4 strains of T. cruzi epimastigote
and metacyclic trypomastigote forms were treated with 10% NHS
during 30 min. Protein extracts of parasites were then subjected
to sodium dodecyl sulfate polyacrylamide gel electrophoresis and
after transferred to nitrocellulose membrane. The membrane was
then incubated with monoclonal mouse anti-human MBL
(1:1000, Antibodyshop, Denmark) and secondly with goat anti-
mouse IgG conjugated with HRP (1:500) (Santa Cruz Biotech) as
described elsewhere [21].
2.5. Parasite invasion assays
The growth of Vero cells and the metacyclic trypomastigote
invasion assays were carried out as described previously [16] with
minor modiﬁcations. Brieﬂy, metacyclic trypomastigotes were
incubated with Vero cells in either 10% NHS, 10% DMBL, 1 lg/mL
of recombinant MBL or serum-free RPMI for three hours at 37 C.
The parasite/cell ratio was 10:1 in all experiments. The rate of
infection was determined by counting the number of intracellular
parasites in 500 cells stained by Giemsa.
2.6. Fluorescence-activated cell sorter (FACS) analysis
FACS analyses were carried out as described previously [5].
Brieﬂy, T. cruzi (1.0  106 parasites) were incubated with NHS at
10% ﬁnal concentration for 1 h at 4 C, washed in PBS, and incu-
bated with anti-MBL (1:1000) in PBS 3% BSA for 1 h at 4 C. Para-
sites were then incubated with anti-mouse IgG-FITC (1:500)
antibodies in PBS 3% BSA for 1 h at 4 C and washed in PBS. We
have established gating on live cells on forward (FSC) v/s side scat-
ter (SSC) plots, where we have discriminated live cells gate than
dead and debris. We also have used single-stained BD™ compbead
particles as compensation controls. After reaction, the parasites
were analyzed with Accuri C6 ﬂow cytometer using CFlow Plus
software (Accuri, Ann Arbor, MI, USA).
2.7. Statistical analysis
All experiments were performed in triplicates. Values are
shown as mean ± 2S.D. Comparisons were made using the un-
paired t-test for repeated measures using GraphPad Prism version
5.04 software (San Diego, California, USA). P < 0.05 was considered
signiﬁcant.3. Results and discussion
In this study, we deﬁned the susceptibility to complement-
mediated lysis of R4 and 860 strains of T. cruzi. We hypothesized
that strains of T. cruzi display MBL acceptors at the plasmatic mem-
brane and use the high MBL concentration in serum to rapidly in-
vade host cells, avoiding successful complement activation.
In our assays we used a pool of DMBL serum and a pool of NHS
to investigate the involvement of MBL in the invasion of metacyclic
tripomastigote forms of T. cruzi to eukaryotic cells and to evaluate
the activation of the lectin complement pathway.
958 I. Evans-Osses et al. / FEBS Letters 588 (2014) 956–961First of all, we analyzed the ability of the different sera to lyse
the epimastigote forms of R4 and 860 strains of T. cruzi. We ob-
served a complete inefﬁciency of DMBL serum to lyse 860 strain
epimastigote forms when compared with the NHS. However, such
strong inﬂuence of MBL at the complement activation was not ob-
served in the lysis of the R4 strain. DMBL serum lysed more than
80% of the R4 parasites in 30 min, which was similar to the lysis
obtained with NHS (85%). These results suggests the involvement
of alternative and classic complement pathways in R4 parasite ly-
sis (Fig. 1A). Taken together, these results of complement-medi-
ated lysis indicate a possible important role of MBL in the lysis of
T. cruzi 860 strain.
To better understand MBL participation in complement-medi-
ated lysis of 860 strain, we investigated the role of alternative path-
way by inhibiting lectin and classic complement pathways using
EGTA-treated serum. Interestingly, the EGTA-treated serum was
not able to lyse parasites at the ﬁrst 15 min and only less than
10% of the parasites were lysed after 30 min, indicating aminor role
of the alternative pathway in the 860 complement mediated lysis
(Fig. 1B). To conﬁrm the role of MBL in the complement-mediated
lysis of 860 strain we evaluated the ability of MBL to restore the ly-
tic effect of complement in DMBL serum. A remarkable restitution
of the complement efﬁciency to lyse the parasites was obtained by
the addition of rMBL to the DMBL serum, thus restoring the func-
tion of the lectin pathway activation. We observed a dose depen-
dent effect by adding 1 and 2 lg/mL rMBL to the DMBL serum,5 
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Fig. 1. R4 and 860 T. cruzi strains differ in the susceptibility to complement mediated
normal or DMBL serum for 30 min. (B) Alternative complement pathway lysis. Epimastig
and 7 mMMg (to inhibit lectin and classical complement pathways). (C) Induction of co
rMBL. Epimastigote forms of 860 strain were incubated with 12% DMBL serum treated wi
to complement-mediated lysis and this is not dependent on the lectin pathway lysis. (E) M
pathway.which resulted in 25–50% of lysis of epimastigote forms of 860
strain (Fig. 1C). Once we deﬁned the effect of the complement sys-
tem in epimastigote forms of both strains, we investigated the com-
plement-mediated lysis of metacyclic trypomastigote forms. Again,
the sensitivity to complement-mediated lysis of metacyclic trypo-
mastigote differed between R4 and 860 strains. Metacyclic forms
of R4 strain presented high sensitivity to complement lysis
(Fig. 1D). By analyzing serial dilutions of NHS and DMBL serum
using R4 strain, we observed a dose dependent effect ranging from
40% to 60% of parasite lysis at 30 min for both serum conditions
(Fig. 1D). However, no lysis was detected in any condition for the
860 strain.
We have already reported empirically that some strains are
resistant to complement lysis and other are sensitive [16] and that
could be crucial to proceed with the infection. Several evasion
mechanisms to the innate immunity have been described for T.
cruzi before, the more effective being the ability to invade host cells
before parasite elimination by the complement system [21].
In order to evaluate whether eukaryotic cell invasion was inﬂu-
enced by the differential susceptibility to complement-mediated
lysis seen for R4 and 860 strains, metacyclic tripomastigote forms
of the parasites were tested in vitro invasion assays using Vero
cells.
The R4 metacyclic invasion was signiﬁcantly increased (3-fold)
when the cells were incubated with 10% NHS, in comparison to the
infection obtained when cells were incubated with DMBL serum orin Co
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lysis. (A) Lysis of epimastigote forms. 860 and R4 strains were incubated with 50%
ote forms of 860 and R4 strains were incubated with NHS treated with 10 mM EGTA
mplement lectin pathway activation using DMBL serum restored with addition of
th 1 or 2 lg/mL rMBL. (D) Metacyclic trypomastigote forms of R4 strain are sensitive
etacyclic trypomastigote forms of 860 strain are resistant to lysis of all complement
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was not signiﬁcantly increased when the metacyclic tripomastig-
otes were opsonized with NHS (Fig. 2C).
These results suggest that components from NHS are stimulat-
ing the R4 parasite invasion into Vero cells, including the deposi-
tion of MBL at the surface of metacyclic tripomastigote forms.
This ability of the parasite surface to bind MBL unveils a ﬁne bal-
ance between the complement activation and the opsonization ef-
fect during the invasion of eukaryotic cells.
The ability of both strains R4 and 860 to bind MBL were inves-
tigated by ﬂow cytometry (Fig. 2A) and by western blotting
(Fig. 2B). We observed a higher deposition of MBL in R4 metacyclic
forms in comparison to 860 strain. This is in agreement with the
interesting pattern of MBL acceptors observed when the parasites
were incubated with NHS and analyzed by western blotting with
anti-human MBL. Fig. 2B shows a band ranking over 100 kDa in
both epimastigote and metacyclic tripomastigote forms of R4 but
not in 860 strain. Indeed, a band about 60 kDa was observed in
both metacyclic strains R4 and 860 and not in epimastigote forms,
suggesting that different MBL acceptors are probably involved in
complement activation or in the invasion process depending on
the strain and evolutive forms of the parasite. This difference
was also observed in ﬂow cytometry where a higher deposition
of MBL at the membrane surface of R4 was observed in comparison
to 860 strain (Fig. 2A). Moreover we have neutralized the effect of
MBL at the R4 invasion and at the Lectin complement pathway
activation pre-treating the NHS with N-acetyl glicosamine and
Mannose, blocking invasion and avoiding lysis of the parasite
(Fig. 2D and E).Fig. 2. (A) Flow cytometry analysis of metacyclic trypomastigotes shows similar MBL bin
1 h at 4 C followed by incubation with anti-human MBL and then with ﬂuorescein isoth
Western blot analysis shows differential MBL deposition between R4 and 860 strains. Ep
incubated in 100 lL of 10% NHS for 30 min at 4 C. Parasite protein extracts were obtaine
Recombinant MBL is shown as a loading control. (C) NHS increased dramatically the invas
strain. Parasites of 860 or R4 strain (1.0  106) were incubated with Vero cells (1.0  105)
10:1) were incubated in serum-free RPMI. Intracellular parasites in at least 500 cells w
block the MBL effect in invasion. R4 strain (1.0  106) were incubated with Vero cells (1.0
3 h at 37 C. As control, parasites and cells (ratio 10:1) were incubated in serum-free RPM
are more resistant to lyse in sugar-treated NHS. 1  105 R4 epimastigotes forms were
mannose (40–80 mM) for 15 min at 37 C.In order to illustrated our hypothesis we have summarized the
effect of our observations in the Fig. 3. In conclusion, NHS revealed
an increased ability of R4 parasites to invade host cells, thus sub-
verting the efﬁciency of complement system in the infection clear-
ance. Moreover, DMBL serum decreased the infection of R4 strain
in eukaryotic cells, suggesting a role of MBL in this process
(Fig. 2A). On the other hand, epimastigote forms of 860 strain were
sensitive to complement-mediated lysis but when differentiate to
metacyclic, they acquired resistance to complement-lysis (Fig. 1B
and D). In addition, NHS and DMBL serum did not inﬂuence the
invasion of 860 strain to host cells. Probably other mechanisms
of complement evasion are working fulltime, avoiding lysis and
inﬂuencing the invasion process (Fig. 3).
The observed resistance to complement lysis of 860 strain may
be very important at the beginning of the infection, where the par-
asites could induce different evasion mechanisms to avoid innate
immunity response and allowing the invasion to eukaryotic cells.
However, R4 strain does not display this kind of evasion mecha-
nism. Differences at the invasion process of R4 strain could be re-
lated to different invasion mechanism. T. cruzi utilize a complex
route of entry into eukaryotic cells involving a wide range of inter-
actions between parasite surface proteins and eukaryotic cell
receptors. The main surface molecules of parasites are glycosilated
and is essential for parasite entry. Moreover, MBL can bind selec-
tively to mannose, glucose, L-fucose and N-acetylglucosamine.
Functional MBL circulate as higher order multimers (tetramer,
pentamer and hexamers) of the structural unit. These structures al-
low high afﬁnity interaction between MBL Carbohydrate recogni-
tion domains (CRDs) and parasites oligosaccharides.ding on both R4 and 860 strains. Parasites (2.0  105) were incubated with NHS for
iocyanate (FITC) conjugated antibody. IgG-FITC was used as an isotype control. (B)
imastigotes and metacyclic trypomastigotes from the two strains (1.0  107) were
d and analyzed by SDS–PAGE and Western blotting with anti-human MBL antibody.
ion of R4 metacyclic trypomastigote forms to host cells, and have no effects over 860
in 10% NHS or 10% DMBL serum for 3 h at 37 C. As control, parasites and cells (ratio
ere counted. (D) NHS treated with N-acetylglicosamine and mannose (40–80 mM)
 105) in 10% NHS or 10% sugar treated-NHS (Mannose and GluNac 40–80 mM) for
I. Intracellular parasites in at least 500 cells were counted. (E) R4 epimastigote forms
incubated with 25% NHS or 25% NHS pre-treated with N-acetylglicosamine and
Fig. 3. Dual function of MBL during parasite–host cell interaction. (A) R4 metacyclic strain is sensitive to complement-mediated lysis, however the parasite uses MBL and
serum factors to invade eukaryotic cells before complement lysis. (B) 860 metacyclic strain displays evasion mechanisms and are resistant to complement-mediated lysis and
invade host cells with no apparent beneﬁt from NHS.
960 I. Evans-Osses et al. / FEBS Letters 588 (2014) 956–961The MBL interaction open the possibility to in same cases neu-
tralize the invasion process blocking antigen-receptor binding.
Similar observation were reported in invasion of intestinal mucosa
by Shigella Flexneri [22] and in the endovascular trophoblast inva-
sion in pre-eclampsia [23].In other cases MBL bind directly to
receptor or as co-factor changing the topology of the membrane
surface by exposing new molecules that facilitate antigen-receptor
contact. Then, signal transduction pathways leading to elevation in
cytosolic Ca2+ concentration in both cells. Disruption of host cell
actin cytoskeleton that follows the interaction with T. cruzi mobi-
lizate lysosomes to the cell periphery contributing for the parasito-
phorus vacuol formation, parasite internalization and in fact,
increasing the invasion [18].
The dual function of MBL during the parasite-host cell interac-
tion seems to be a novel evasion mechanism of pathogens in order
to subvert innate immunity and increase invasion of eukaryotic
cells.
Differential role of MBL with different T. Cruzi strains may help
better understand the mechanism involved in the interaction be-
tween the host and parasite. Overall our study provides a better
understanding on the underlying mechanism of MBL in establish-
ment of CD.
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